CI
EBS icon

Cambiar Investors’s Emergent Biosolutions EBS Stock Holding History

Cambiar Investors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-59,866
Closed -$2.46M – 150
2022
Q1 		$2.46M Buy
59,866
+1,937
+3% +$85.4K 0.09% 113
2021
Q4 		$2.52M Buy
57,929
+18,296
+46% +$828K 0.09% 119
2021
Q3 		$1.98M Sell
39,633
-485
-1% -$29.4K 0.07% 134
2021
Q2 		$2.53M Buy
40,118
+8,343
+26% +$536K 0.08% 137
2021
Q1 		$2.95M Buy
31,775
+9,157
+40% +$938K 0.1% 109
2020
Q4 		$2.03M Buy
22,618
+4,331
+24% +$398K 0.08% 137
2020
Q3 		$1.89M Sell
18,287
-12,208
-40% -$1.32M 0.09% 131
2020
Q2 		$2.41M Sell
30,495
-2,138
-7% -$159K 0.11% 88
2020
Q1 		$1.89M Sell
32,633
-9,091
-22% -$524K 0.09% 97
2019
Q4 		$2.25M Sell
41,724
-2,123
-5% -$115K 0.07% 121
2019
Q3 		$2.29M Sell
43,847
-8,221
-16% -$383K 0.07% 119
2019
Q2 		$2.52M Buy
+52,068
New +$2.5M 0.07% 122

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cambiar Investors's EBS Position: Q2 2022 in Review

Cambiar Investors sold out of Emergent Biosolutions (EBS) in Q2 2022, closing a stake of 59,866 shares — an estimated $2.46M sold.

Cambiar Investors first reported a position in EBS in Q2 2019 and held it in 12 quarters. The position peaked at $2.95M in Q1 2021. 232 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

  • Cambiar Investors reported no remaining Emergent Biosolutions position as of Q2 2022 after selling out during the quarter.
  • Cambiar Investors sold 59,866 Emergent Biosolutions shares in Q2 2022, an estimated $2.46M.
  • Cambiar Investors first reported a position in Emergent Biosolutions in Q2 2019 and held it in 12 quarters.
  • Cambiar Investors's Emergent Biosolutions position peaked at $2.95M in Q1 2021.
  • 232 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on Cambiar Investors's 13F filing for Q2 2022, filed 5 Aug 2022.